Overview
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Status:
Recruiting
Recruiting
Trial end date:
2022-12-31
2022-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
SK Life Science, Inc.
Criteria
Inclusion Criteria:- Subjects who completed the YKP509C001 study
- Investigator believes subject could benefit from continued exposure to study drug
- Subjects must continue to meet all of the inclusion criteria from the YKP509C001 study
Exclusion Criteria:
- Subjects must continue to not meet any of the exclusion criteria from the YKP509C001
study
- There are no additional exclusion criteria in this study